Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis

被引:83
作者
Baldwin, C
Nolan, VG
Wyszynski, DF
Ma, QL
Sebastiani, P
Embury, SH
Bisbee, A
Farrell, J
Farrer, L
Steinberg, MH
机构
[1] Boston Univ, Sch Med, Ctr Human Genet, Dept Pediat, Boston, MA 02118 USA
[2] Boston Univ, Sch Med, Ctr Human Genet, Dept Med, Boston, MA 02118 USA
[3] Boston Univ, Sch Publ Hlth, Boston, MA USA
[4] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[5] San Francisco Gen Hosp, San Francisco, CA 94110 USA
关键词
D O I
10.1182/blood-2005-02-0548
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In patients with sickle cell disease, clinical complications including osteonecrosis can vary in frequency and severity, presumably due to the effects of genes that modify the pathophysiology initiated by the sickle mutation. Here, we examined the association of single nucleotide polymorphisms (SNPs) in candidate genes (cytokines, inflammation, oxidant stress, bone metabolism) with osteonecrosis in patients with sickle cell disease. Genotype distributions were compared between cases and controls using multiple logistic regression techniques. An initial screen and follow-up studies showed that individual SNPs and haplotypes composed of several SNPs in bone morphogenic protein 6, annexin A2, and klotho were associated with sickle cell osteonecrosis. These genes are important in bone morphology, metabolism, and vascular disease. Our results may provide insight into the pathogenesis of osteonecrosis in sickle cell disease, help identify individuals who are at high risk for osteonecrosis, and thus allow earlier and more effective therapeutic intervention.
引用
收藏
页码:372 / 375
页数:4
相关论文
共 22 条
[1]   Haploview: analysis and visualization of LD and haplotype maps [J].
Barrett, JC ;
Fry, B ;
Maller, J ;
Daly, MJ .
BIOINFORMATICS, 2005, 21 (02) :263-265
[2]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[3]   Identification of novel inhibitors of the transforming growth factor β1 (TGF-β1) type 1 receptor (ALK5) [J].
Callahan, JF ;
Burgess, JL ;
Fornwald, JA ;
Gaster, LM ;
Harling, JD ;
Harrington, FP ;
Heer, J ;
Kwon, C ;
Lehr, R ;
Mathur, A ;
Olson, BA ;
Weinstock, J ;
Laping, NJ .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (05) :999-1001
[4]  
GASTON M, 1987, CONTROL CLIN TRIALS, V8, pS131
[5]  
GASTON M, 1982, AM J PEDIAT HEMATOL, V4, P197
[6]   The role of annexin 2 in osteoblastic mineralization [J].
Gillette, JM ;
Nielsen-Preiss, SM .
JOURNAL OF CELL SCIENCE, 2004, 117 (03) :441-449
[7]   SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7 [J].
Inman, GJ ;
Nicolás, FJ ;
Callahan, JF ;
Harling, JD ;
Gaster, LM ;
Reith, AD ;
Laping, NJ ;
Hill, CS .
MOLECULAR PHARMACOLOGY, 2002, 62 (01) :65-74
[8]   Ectopic osteogenesis using adenoviral bone morphogenetic protein (BMP)-4 and BMP-6 gene transfer [J].
Jane, JA ;
Dunford, BA ;
Kron, A ;
Pittman, DD ;
Sasaki, T ;
Li, JZ ;
Li, HW ;
Alden, TD ;
Dayoub, H ;
Hankins, GR ;
Kallmes, DF ;
Helm, GA .
MOLECULAR THERAPY, 2002, 6 (04) :464-470
[9]   cDNA microarray analysis of changes in gene expression induced by neuronal hypoxia in vitro [J].
Jin, K ;
Mao, XO ;
Eshoo, MW ;
del Rio, G ;
Rao, R ;
Chen, D ;
Simon, RP ;
Greenberg, DA .
NEUROCHEMICAL RESEARCH, 2002, 27 (10) :1105-1112
[10]   Inhibition of transforming growth factor (TGF)-β1-induced extracellular matrix with a novel inhibitor of the TGF-β type I receptor kinase activity:: SB-431542 [J].
Laping, NJ ;
Grygielko, E ;
Mathur, A ;
Butter, S ;
Bomberger, J ;
Tweed, C ;
Martin, W ;
Fornwald, J ;
Lehr, R ;
Harling, J ;
Gaster, L ;
Callahan, JF ;
Olson, BA .
MOLECULAR PHARMACOLOGY, 2002, 62 (01) :58-64